FibroGen, Inc. – NASDAQ:FGEN

FibroGen stock price today

$10.9
+10.32
+1779.31%
Financial Health
0
1
2
3
4
5
6
7
8
9

FibroGen stock price monthly change

-44.23%
month

FibroGen stock price quarterly change

-44.23%
quarter

FibroGen stock price yearly change

-28.32%
year

FibroGen key metrics

Market Cap
42.05M
Enterprise value
1.67B
P/E
-5.68
EV/Sales
11.89
EV/EBITDA
-5.96
Price/Sales
12.36
Price/Book
-81.15
PEG ratio
6.08
EPS
-2.44
Revenue
167.49M
EBITDA
-214.53M
Income
-240.46M
Revenue Q/Q
54.59%
Revenue Y/Y
44.30%
Profit margin
-208.66%
Oper. margin
-213.9%
Gross margin
85.59%
EBIT margin
-213.9%
EBITDA margin
-128.09%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

FibroGen stock price history

FibroGen stock forecast

FibroGen financial statements

FibroGen, Inc. (NASDAQ:FGEN): Profit margin
Jun 2023 44.31M -87.68M -197.84%
Sep 2023 40.13M -63.61M -158.51%
Dec 2023 27.13M -56.23M -207.21%
Mar 2024 55.90M -32.93M -58.91%
FibroGen, Inc. (NASDAQ:FGEN): Analyst Estimates
Sep 2025 49.14M 22.70M 46.19%
Oct 2025 36.51M 4.94M 13.55%
Dec 2025 37.02M 5.93M 16.04%
Mar 2026 50.01M 26.08M 52.15%
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
FibroGen, Inc. (NASDAQ:FGEN): Payout ratio
Payout ratio 0%
FibroGen, Inc. (NASDAQ:FGEN): Dividend Yield
2019
2020
2021
2022
2023 2.61%
FibroGen, Inc. (NASDAQ:FGEN): Debt to assets
Jun 2023 515127000 575.43M 111.71%
Sep 2023 460426000 575.62M 125.02%
Dec 2023 423529000 585.72M 138.3%
Mar 2024 365868000 552.02M 150.88%
FibroGen, Inc. (NASDAQ:FGEN): Cash Flow
Jun 2023 -110.57M -14.28M 91.53M
Sep 2023 -84.53M 54.21M -22K
Dec 2023 -18.32M 10.24M -246K
Mar 2024 -59.28M 51.27M -165K

FibroGen alternative data

FibroGen, Inc. (NASDAQ:FGEN): Employee count
Aug 2023 592
Sep 2023 592
Oct 2023 592
Nov 2023 592
Dec 2023 592
Jan 2024 592
Feb 2024 592
Mar 2024 486
Apr 2024 486
May 2024 486
Jun 2024 486
Jul 2024 486

FibroGen other data

72.22% +0.79%
of FGEN is owned by hedge funds
67.02M +732.14K
shares is hold by hedge funds

FibroGen, Inc. (NASDAQ:FGEN): Insider trades (number of shares)
Period Buy Sel
Jul 2023 0 3880
Aug 2023 0 2000
Sep 2023 0 2000
Mar 2024 50000 0
Jun 2024 22123 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ADIB DEYAA officer: Chief Medical Officer
Common Stock 22,123 $1.17 $25,884
Purchase
WETTIG THANE officer: CEO Common Stock 50,000 $1.91 $95,450
Sale
HENDERSON JEFFREY WILLIAM director
Common Stock 2,000 $1.03 $2,060
Sale
HENDERSON JEFFREY WILLIAM director
Common Stock 2,000 $1.91 $3,820
Sale
HENDERSON JEFFREY WILLIAM director
Common Stock 2,000 $2.69 $5,380
Sale
CONTERNO ENRIQUE A director, officer.. Common Stock 1,880 $2.8 $5,264
Sale
CONTERNO ENRIQUE A director, officer.. Common Stock 1,880 $2.8 $5,264
Sale
WETTIG THANE officer: Chief Co.. Common Stock 791 $16.53 $13,075
Sale
CHUNG CHRISTINE officer: SVP, China Operations
Common Stock 5,250 $16.66 $87,465
Sale
CHUNG CHRISTINE officer: SVP, China Operations
Common Stock 1,000 $17.46 $17,460
Patent
Application
Filling date: 27 Jan 2022 Issue date: 19 May 2022
Application
Filling date: 19 Jan 2022 Issue date: 12 May 2022
Application
Filling date: 10 Mar 2021 Issue date: 24 Feb 2022
Application
Filling date: 21 May 2020 Issue date: 26 Nov 2020
Monday, 16 December 2024
globenewswire.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Monday, 4 November 2024
globenewswire.com
Friday, 9 August 2024
seekingalpha.com
Tuesday, 6 August 2024
zacks.com
Wednesday, 31 July 2024
benzinga.com
investorplace.com
investorplace.com
Tuesday, 30 July 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
globenewswire.com
Tuesday, 28 May 2024
investorplace.com
Thursday, 23 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Monday, 6 May 2024
Seeking Alpha
Monday, 29 April 2024
GlobeNewsWire
Wednesday, 20 March 2024
InvestorPlace
Monday, 26 February 2024
Reuters
Tuesday, 20 February 2024
GlobeNewsWire
Monday, 6 November 2023
Seeking Alpha
Zacks Investment Research
Monday, 23 October 2023
GlobeNewsWire
Thursday, 19 October 2023
InvestorPlace
Wednesday, 30 August 2023
Zacks Investment Research
Proactive Investors
Market Watch
Wednesday, 16 August 2023
Zacks Investment Research
Monday, 7 August 2023
Seeking Alpha
  • What's the price of FibroGen stock today?

    One share of FibroGen stock can currently be purchased for approximately $10.9.

  • When is FibroGen's next earnings date?

    Unfortunately, FibroGen's (FGEN) next earnings date is currently unknown.

  • Does FibroGen pay dividends?

    No, FibroGen does not pay dividends.

  • How much money does FibroGen make?

    FibroGen has a market capitalization of 42.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.99% to 147.75M US dollars.

  • What is FibroGen's stock symbol?

    FibroGen, Inc. is traded on the NASDAQ under the ticker symbol "FGEN".

  • What is FibroGen's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of FibroGen?

    Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are FibroGen's key executives?

    FibroGen's management team includes the following people:

    • Mr. Enrique A. Conterno Chief Executive Officer & Director(age: 58, pay: $1,640,000)
    • Dr. Elias Kouchakji Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance(age: 69, pay: $893,280)
    • Mr. Pat Cotroneo Executive Advisor to Chief Executive Officer(age: 61, pay: $797,900)
    • Mr. Thane Wettig Chief Commercial Officer(age: 60, pay: $583,030)
    • Dr. Mark Eisner M.D., M.P.H. Chief Medical Officer(age: 59, pay: $554,290)
    • Mr. James A. Schoeneck Chairman(age: 67, pay: $415,260)
  • How many employees does FibroGen have?

    As Jul 2024, FibroGen employs 486 workers.

  • When FibroGen went public?

    FibroGen, Inc. is publicly traded company for more then 10 years since IPO on 14 Nov 2014.

  • What is FibroGen's official website?

    The official website for FibroGen is fibrogen.com.

  • Where are FibroGen's headquarters?

    FibroGen is headquartered at 409 Illinois Street, San Francisco, CA.

  • How can i contact FibroGen?

    FibroGen's mailing address is 409 Illinois Street, San Francisco, CA and company can be reached via phone at +41 59781200.

FibroGen company profile:

FibroGen, Inc.

fibrogen.com
Exchange:

NASDAQ

Full time employees:

486

Industry:

Biotechnology

Sector:

Healthcare

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

409 Illinois Street
San Francisco, CA 94158

CIK: 0000921299
ISIN: US31572Q8087
CUSIP: 31572Q808